Prosecution Insights
Last updated: October 25, 2026
Application No. 19/099,176

ORAL CARE COMPOSITION AND METHOD FOR PREPARING ORAL CARE COMPOSITION

Non-Final OA §102§103
Filed
Jan 28, 2025
Priority
Jul 29, 2022 — RE 10-2022-0094833 +2 more
Examiner
PURDY, KYLE A
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
LG H&H Co. Ltd.
OA Round
1 (Non-Final)
41%
Grant Probability
Moderate
1-2
OA Rounds
2y 5m
Est. Remaining
77%
With Interview

Examiner Intelligence

Grants 41% of resolved cases
41%
Career Allowance Rate
410 granted / 1001 resolved
-19.0% vs TC avg
Strong +36% interview lift
Without
With
+35.7%
Interview Lift
resolved cases with interview
Typical timeline
4y 2m
Avg Prosecution
71 currently pending
Career history
1085
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
62.9%
+22.9% vs TC avg
§102
13.8%
-26.2% vs TC avg
§112
14.3%
-25.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1001 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement The information disclosure statement (IDS) submitted on 1/28/2025 was considered by the examiner. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-4 rejected under 35 U.S.C. 102(a)(1) as being anticipated by Baig et al. (US 2016/0324741), evidenced by Cao et al. (Korean J Chem Eng, 18(1), 2001, 133-135). Baig discloses an aqueous oral care composition comprising a zinc source, e.g. zinc lactate, and a tin source, e.g. stannous chloride, stannous fluoride, stannous gluconate (see claims 1, 17-19; see instant claims 1-3). Zinc lactate has a water solubility dependent on temperature with a solubility of 4.22% at 10oC and 12.16% at 80oC (see page 134 of evidence/Cao). Baig’s oral care composition comprises a buffer (pH adjuster) and an abrasive (e.g. silica) (see [0046, 0049], claim 9; see instant claim 4), wherein the composition has a pH of 3-10, or more narrowly between 4-7 (see [0049]). It is observed that a pH of 10 and 7 are within the range of instant claim 5. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 6-8 are is/are rejected under 35 U.S.C. 103 as being unpatentable over Baig et al. (US 2016/0324741), evidenced by Cao et al. (Korean J Chem Eng, 18(1), 2001, 133-135). Baig is relied upon for disclosure described in the rejection of claims 1-5 under 35 U.S.C. 102(a)(1). Methods of preparing the aqueous oral care composition are provided wherein stannous fluoride (obvious/interchangeable variant of stannous chloride, see claim 19) is provided to a solution comprising sodium gluconate, adding sodium hydroxide (a buffering agent/pH adjuster (see [0050]) and then combining this mixture with a solution comprising zinc lactate (source of zinc ions) (see Cao above regarding zinc lactate solubility) (see Example 6, [0131]). Although the steps described by Baig do not perfectly align with that claimed, MPEP 2144.04(IV)(C) states that changes in the sequence of adding ingredients is an obvious manipulation absent some new or unexpected outcome (of which none is presently known). Therefore, the invention as a whole is prima facie obvious to one of ordinary skill in the art at the time the invention was filed, as evidenced by the references, especially in absence of evidence to the contrary. Unapplied relevant prior art Strand et al., EP 2057978 Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to KYLE A PURDY whose telephone number is (571)270-3504. The examiner can normally be reached from 9AM to 5PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bethany Barham, can be reached on 571-272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /KYLE A PURDY/Primary Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Jan 28, 2025
Application Filed
Sep 01, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767635
LIPOXYGENASE INHIBITORS
4y 1m to grant Granted Oct 20, 2026
Patent 12765549
METHOD OF USING/APPLYING A KERATIN HYDROLYSIS PEPTIDE SOLUTION TO PROMOTE TOLERANCE OF SOYBEAN AND ITS GROWTH UNDER STRESS OF FLOODING
2y 5m to grant Granted Oct 20, 2026
Patent 12758677
MATERIALS AND METHODS FOR DEODORIZATION OF MAMMALIAN URINE
2y 6m to grant Granted Oct 13, 2026
Patent 12734206
COMPOSITION FOR HANGOVER RELIEF COMPRISING NONI FRUIT EXTRACT OR FRACTION THEREOF AND USE THEREOF
3y 4m to grant Granted Sep 15, 2026
Patent 12721345
ULTRAFINE GOLD NANOCOMPOSITE, AND PREPARATION METHOD AND USE THEREOF
2y 9m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
41%
Grant Probability
77%
With Interview (+35.7%)
4y 2m (~2y 5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1001 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month